New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
October 14, 2022 - The FDA approved Eli Lilly’s Lyumjev (insulin lispro-aabc), to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Download PDF
Return to publications
